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ABSTRACT 
Background: The Unified Huntington’s Disease Rating Scale (UHDRS) is the principal means of assessing motor 
impairment in Huntington disease but is subjective and generally limited to in-clinic assessments.  
Objective: To evaluate the feasibility and ability of wearable sensors to measure motor impairment in individuals 
with Huntington disease in the clinic and at home.  
Methods: Participants with Huntington disease and controls were asked to wear five accelerometer-based 
sensors attached to the chest and each limb for standardized, in-clinic assessments and for one day at home. A second 
chest sensor was worn for six additional days at home. Gait measures were compared between controls, participants 
with Huntington disease, and participants with Huntington disease grouped by UHDRS total motor score using Cohen’s d 
values.  
Results: Fifteen individuals with Huntington disease and five controls completed the study. Sensor data were 
successfully captured from 18 of the 20 participants at home. In the clinic, the standard deviation of step time (time 
between consecutive steps) was increased in Huntington disease (p<0.0001; Cohen’s d=2.61) compared to controls. At 
home with additional observations, significant differences were observed in seven additional gait measures. The gait of 
individuals with higher total motor scores (50 or more) differed significantly from those with lower total motor scores 
(below 50) on multiple measures at home.   
Conclusions: In this pilot study, the use of wearable sensors in clinic and at home was feasible and demonstrated 
gait differences between controls, participants with Huntington disease, and participants with Huntington disease 
grouped by motor impairment.  
Keywords: Huntington disease, remote sensing technology, clinical study, movement, gait, chorea, ambulatory 
monitoring 
INTRODUCTION 
The principal means of measuring motor impairment in Huntington disease (HD) is the Unified Huntington’s 
Disease Rating Scale (UHDRS) total motor score [1]. Although valuable, the scale is subjective and categorical [2,3], 
requires significant training to administer correctly, and only captures impairment in clinic. Quantitative motor tests, 
notably “Q-Motor” assessments, have helped reduce subjectivity and improve sensitivity of motor assessments in HD [4-
11]. Q-Motor assessments have demonstrated utility in tracking longitudinal progression of motor impairment [12,13] 
and as a supplemental measure in clinical trials [14]. Likewise, force-sensitive insoles [15,16], video motion analysis 
systems [17], and pressure-sensitive walking mats [18-20] have been utilized to objectively measure impaired gait in 
Huntington disease. However, these gait-measuring technologies and Q-Motor assessments must be administered in 
clinic by trained personnel.  
If effective, wearable sensors could enable objective, sensitive, continuous assessment of individuals both in clinic 
and remotely from home. Previous studies have demonstrated the feasibility and promise of wearable sensors as 
objective measures of motor impairment in Parkinson disease [21-24]. However, few, if any, published studies have 
examined such an application in HD. We therefore conducted a pilot study of wearable sensors in clinic and at home in 
individuals with HD and controls to determine their feasibility and potential utility.  
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MATERIALS AND METHODS 
Study overview and design 
We conducted a seven- day, observational study using accelerometer-based, wearable PAMSys-X™ sensors 
[25,26] (BioSensics, Cambridge, MA; $2,300 per sensor set) in individuals with HD and controls. Study goals included (1) 
determining the feasibility of capturing motor assessments with sensors at home, (2) comparing sensor data between 
participants with HD and controls, and (3) comparing sensor data by motor impairment as measured by the UHDRS total 
motor score. Participants gave informed, written consent for this study and all procedures were approved by the 
University of Rochester’s institutional review board. 
 Participants with HD had a clinical diagnosis, either a first degree relative with HD or confirmatory genetic 
testing (CAG expansion ≥36), and a UHDRS total maximal chorea score ≥4 at screening. Unaffected family and friends of 
participants with HD were recruited as controls. Unaffected family members at risk for HD had previously undergone 
genetic testing confirming absence of CAG expansion. In clinic, participants provided basic demographic data, completed 
a survey on technology use, and underwent the Montreal Cognitive Assessment [27]. Participants were then fitted with 
five sensors affixed by adjustable bands to their ankles, wrists, and chest (Figure 1) and were video recorded while 
performing the UHDRS motor, Timed Up and Go [28], and Q-Motor assessments. At home, all five sensors were worn for 
24 hours (i.e., day 1) and then a replacement chest sensor was worn for an additional six days (i.e., days 2-7). 
Participants were instructed to remove the non-waterproof sensors when bathing and were given the option to remove 
them at night, for comfort, while sleeping. Participants mailed the sensors back to BioSensics for data analysis and 
completed a survey on their experience wearing and perceived utility of the sensors.  HD participants with significant 
cognitive impairment were assisted by family members to ensure all study related activities were completed. 
Analysis 
Sensor data analyzed: Tri-axial acceleration data were collected from sensors at a sampling rate of 50 Hz. Only the 
chest sensor was required for data analysis presented in this paper; wrist and ankle sensor analysis is ongoing and is not 
included in this report.  
Physical activity: Using days 2-7 chest sensor data, active (i.e., non-passive) physical activity measures, including 
time spent sitting, standing, walking, and running, the total number and duration of sit-to-stand and stand-to-sit 
transitions, and the total number of walking episodes, steps, and steps per walking episode were computed using 
commercially available software (PAMWare™, BioSensics, Cambridge, MA). The software’s physical activity analysis 
algorithms have been described previously [25]. These algorithms use pattern recognition to detect sit-to-stand and 
stand-to-sit transitions from tri-axial chest acceleration data and a filtering and peak finding scheme to identify episodes 
of walking from the vertical axis acceleration data.  
Gait: Using chest sensor data from days 1 through 7, algorithms were developed to isolate equally weighted 
walking windows from which gait measures were computed. Using the peak finding scheme from the physical activity 
analysis software [25], walking episodes defined by 10 or more steps were identified. Within these walking episodes, 
gait measure values were computed from 15-second windows of data with 50% overlap. This overlap was used to ensure 
that gait cycle events at the beginning or end of a window were not missed. In-clinic gait measures were derived from 
one walking window during the Timed Up and Go test. Velocity and displacement were calculated from acceleration 
data by trapezoidal numerical integration and double integration, respectively. Samples of the following gait measures 
were computed for each isolated 15-second walking window: 
Step time standard deviation: Standard deviation of the time between consecutive steps 
Cadence: Number of steps per unit time 
Step peak acceleration: Maximum and average of the peak acceleration value for each step, which is representative of 
an individual’s heel strike force during footfall  
Medial-lateral speed: Maximum and average speed in the side-to-side plane  
Medial-lateral displacement: Maximum and average distance in the side-to-side plane 
Grouping data and statistics 
For comparing HD versus control, two-tailed, equal variance, unpaired t-tests (α=0.05) were used. For comparing 
total motor score 50, total motor score <50, and control, one-way analyses of variance were performed followed by (if 
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appropriate) Tukey-Kramer multiple comparison tests (α=0.05). A total motor score of 50 was chosen based mainly on a 
bimodal distribution. Effect sizes were computed for comparisons using Cohen’s d (absolute values).   
RESULTS 
Study population and feasibility 
Fifteen participants with HD and five controls completed the one-week study. On average, participants with HD 
were 56.8 (± 6.6) years old, had manifest HD for 7.7 (± 4.9) years, and had a total motor score of 42.3 (± 13.3) and a total 
maximal chorea score of 9.1 (± 3.5). On average, controls were 53.4 (± 20.4) years old (Table 1). Data were successfully 
obtained from all participants except for days 2-7 chest sensor recordings for two participants with HD. One sensor had 
no recorded data, and one sensor had corrupted data due to damage to the memory card. One participant with HD lost 
an ankle sensor. 
Physical activity analysis 
At home, the time spent sitting upright, standing, walking, and running were similar between controls and 
participants with HD (Figure 2). The total number and duration of sit-to-stand and stand-to-sit transitions and the total 
number of walking episodes, steps, and steps per walking episode were also similar between controls and participants 
with HD (data not shown).  
Gait analysis: control vs. HD 
In clinic, each participant had one 15-second walking window analyzed. At home (with longer periods of 
observation), the number of 15-second walking windows was 14,017 for controls and 36,088 for participants with HD. In 
clinic, step time standard deviation was increased in HD (p<0.0001; Cohen’s d=2.61) (Figure 3A). At home, differences 
were observed between controls and participants with HD for all eight gait measures (p<0.0001) (Figures 3A-H). Notably, 
gait cadence was reduced in HD (104.4 ± 12.1 steps per minute) compared to controls (118.8 ± 15.5 steps per minute) 
(Cohen’s d=1.10) (Figure 3B). 
Gait analysis: control vs. HD grouped by total motor score 
Of participants with HD, five had a total motor score of at least 50 and 10 had a total motor score of less than 50. 
However, data from days 2-7 for two participants with total motor scores less than 50 were not successfully captured.   
In clinic, step time standard deviation was increased in both sub-groups of participants with HD relative to 
controls (p<0.001; Cohen’s d2.94) (Figure 4A). Average step peak acceleration was also increased, in clinic, in those 
with a total motor score 50 relative to controls (p<0.05; Cohen’s d=3.03) (Figure 4D). At home, as the number of 
walking windows analyzed per group increased, all eight gait measures differed between all three groups (p<0.01) and 
differed between those with higher and lower total motor scores (Figures 4A-H).  
Survey 
The post-study survey was completed by all 20 participants. The majority found the sensors to be “comfortable” 
(n = 16) and “easy to use” (n = 17). The most common complaint was that the chest sensor’s strap was uncomfortable. 
When asked if they would use these sensors if asked in the future, 11 of the 15 participants with HD said they would be 
“very willing.”  
DISCUSSION 
In this pilot study, the use of wearable sensors at home was feasible, well tolerated, and demonstrated 
differences in gait among controls, participants with HD, and participants with HD grouped by motor impairment. With 
more observations (and thus greater power) at home, additional differences in gait were detected.  In the uncontrolled 
setting of the home, the variability in the motor measures detected by the sensors was generally greater than those 
observed in the controlled clinical environment.  However, the vastly greater frequency of observations and thus greater 
power enabled detection of significant differences.   
The results from this study are generally consistent with previous gait assessments conducted in clinic. For 
example, in-clinic measures have previously shown increased step time variability in HD that increases with disease 
severity [15,19] and that can differentiate individuals with pre-manifest HD from controls [19]. In this study, in-clinic and 
at-home results revealed step time standard deviation to be the most sensitive gait measure. Step time standard 
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deviation was the sole gait measure found to be different between controls and participants with HD both in clinic and 
at home. Moreover, relative to other gait measures, step time standard deviation showed the largest effect size when 
comparing at-home results among individuals with HD grouped by total motor score.   
Previous studies have also shown that gait cadence is decreased in HD through in-clinic evaluations [16-19,29]. 
This study demonstrates that gait cadence is also decreased when measured at home. In addition, the values of at-home 
steps per minute for controls and participants with HD are very similar to values measured in clinic [16-19].  
Medial-lateral velocity and displacement were found to be increased in HD at home. Among these side-to-side 
movement measures during walking, average medial-lateral velocity had the largest effect size when comparing controls 
to participants with HD. Previously, using a lower back-attached angular velocity transducer, Grimbergen et al. [20] 
found medial-lateral trunk sway during walking to be increased in HD and increased in a group of HD “fallers” (with a 
higher total motor score) relative to “non-fallers.” Based on clinical correlation, they attributed trunk sway during 
walking to chorea. 
This pilot study’s limitations include its small sample size and short duration. In addition, the magnitude of 
differences observed in gait, especially at home, was in some cases small, especially among the two sub-groups of 
individuals with HD. In the future, larger, longer duration studies of wearable sensors will need to further evaluate 
feasibility, test re-test reliability, and correlate results with standard clinical, and quantitative motor assessments.Larger 
studies could also include those with prodromal HD and even more advanced HD.  While small, this study did suggest 
that those with modest cognitive impairment could wear sensors.   
In addition, future studies could evaluate the ability of sensors to detect changes in response to medications 
known to improve motor function [30], which could support their greater use in clinical research and potentially patient 
care. High frequency, objective data acquired in a “real world” setting could also be used to evaluate promising 
therapeutics in early stage clinical trials and offer the potential to reduce sample size, time, and cost of such trials [3]. 
Much work remains before evaluating and realizing this promise, but hopefully this study begins to lay the foundation 
for future evaluations of wearable sensors for assessing important external manifestations of HD. 
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Table 1. Baseline characteristics of the study population 
 
  
HD 
(n = 15) 
Controls 
(n = 5) 
Demographics 
  
  Age (years) 56.8 ± 6.6 53.4 ± 20.4 
  Women [%] 40 60 
  White [%] 100 100 
  Hispanic ethnicity [%] 0 0 
  4-year college degree or higher education [%] 40 60 
  Currently employed or a student [%] 0 60 
  Currently married or in a domestic partnership [%] 60 20 
HD Characteristics 
  
  Years since diagnosis 7.7 ± 4.9 
 
  Currently seeing an HD specialist [%] 100 
 
  UHDRS total motor score (0-124) 42.3 ± 13.3 
 
  UHDRS total maximal chorea score (0-28) 9.1 ± 3.5 
 
  Timed Up and Go (seconds) 16.2 ± 5.2 11.7 ± 2.8 
  10 Meter Walk Test (seconds) 12.2 ± 5.5 7.5 ± 1.1 
  Montreal Cognitive Assessment score (0-30) 21.5 ± 3.7 28.2 ± 0.8 
Internet and Technology Use 
  
  Use Internet or email [%] 80 80 
  Have used Internet to look up health information [%] 73 80 
  Have used smartphone or tablet to access Internet 
[%] 
27 60 
  Have used computer or other device to video chat 
[%] 
27 60 
 
Values are mean ± standard deviation unless noted as [%] 
UHDRS, Unified Huntington’s Disease Rating Scale 
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Figure 1. Picture of wearable chest, ankle, and wrist sensors used in the study. 
 
 
 
 
Figure 2. Active (i.e., non-passive) physical activity measures comparing controls and participants with 
HD. 
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Figure 3. In-clinic and at-home gait measures comparing controls and participants with HD (*p<0.05; 
**p<0.01; ***p<0.001; ****p<0.0001). 
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Figure 4. In-clinic and at-home gait measures comparing controls and participants with HD grouped by 
total motor score (*p<0.05; **p<0.01; ***p<0.001; ****p<0.0001). 
 
